Xing Wei Wang

US Patent:

7415360, Aug 19, 2008

Filed:

Mar 27, 2004

Appl. No.:

10/810296

Inventors:

Xing Fa Wang - Worcester MA, US

International Classification:

G06F 19/00
G06F 17/10
G01N 31/00
G05B 21/00

US Classification:

702 19, 700266, 702 22, 703 2

Abstract:

The present invention is a multiparameter method of screening for the diagnosis, prevention or treatment of atherosclerosis-related coronary heart disease (CHD) or stroke. This method is used for predicting a total risk of the disease and a disease risk level, determining a primary cause in the disease, assessing a therapeutic efficacy and optimizing the therapeutic targets at the different stages of the disease in different individuals who require the therapy to prevent or to treat the disease. The method of this invention can be used to combine the contributions of atherosclerotic risk factors to the disease and to unite the two major methods for diagnosing the disease: screening the Low-density lipoprotein (LDL) level and measuring the C-reactive protein (CRP) concentration in human blood. The method of this invention is written as an executable computer program named the MMA. exe 2004, by Xing F.

US Patent:

20190194315, Jun 27, 2019

Filed:

Jun 17, 2016

Appl. No.:

15/737042

Inventors:

Tinya ABRAMS - Acton MA, US
Steven Bruce COHEN - San Diego CA, US
Joseph Anthony D'Alessio - Boston MA, US
Jason Damiano - Oakland CA, US
Clemens Durr - Weil am Rhein, DE
Bernhard Hubert GEIERSTANGER - Solana Beach CA, US
Thomas HUBER - Basel, CH
Hidetomo IMASE - Somerville MA, US
Yunho JIN - San Diego CA, US
Daniel MENEZES - Berkeley CA, US
Kathy MILLER - San Francisco CA, US
Morvarid MOHSENI - Boston MA, US
Weijia OU - San Diego CA, US
Katherine RENDAHL - Berkeley CA, US
Tetsuo UNO - San Diego CA, US
Yongqin WAN - San Diego CA, US
Xing WANG - San Diego CA, US

Assignee:

Novartis AG - Basel

International Classification:

C07K 16/28
A61K 47/65
A61K 47/68
A61P 35/00
A61K 38/07

Abstract:

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.